Literature DB >> 9766655

Role of E2F-1 in chemosensitivity.

D Banerjee1, B Schnieders, J Z Fu, D Adhikari, S C Zhao, J R Bertino.   

Abstract

The E2F family of transcription factors, in partnership with DP proteins, is thought to regulate transcription of genes that encode protein products that are required for DNA synthesis, which include important cancer chemotherapeutic targets such as thymidylate synthase and dihydrofolate reductase. This study was conducted to investigate the effects of overexpression of human E2F-1 cDNA on chemosensitivity in a human fibrosarcoma cell line, HT-1080. The E2F-1-overexpressing HT-1080 cells had a shorter doubling time both in vitro and in vivo. Associated with an up-regulation of TS, E2F-1-transfected cells were more resistant to 5-fluorouracil than were untransfected cells. These E2F-1 transfectants, although resistant to fluoropyrimidines and serum deprivation, were more sensitive to etoposide, doxorubicin, and SN38 (the active metabolite of irinotecan) but not to Taxol.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9766655

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  Leucovorin and fluorouracil plus oxaliplatin or leucovorin and fluorouracil plus irinotecan as individualized first-line therapy based on a drug sensitivity test.

Authors:  Takumi Ochiai; Kazuhiko Nishimura; Tomoo Watanabe; Masayuki Kitajima; Tadasuke Hashiguchi; Akinori Nakatani; Takashi Marusasa; Akira Muraki; Isao Nagaoka; Shunji Futagawa
Journal:  Exp Ther Med       Date:  2010-03-01       Impact factor: 2.447

2.  Functional interplay between E2F1 and chemotherapeutic drugs defines immediate E2F1 target genes crucial for cancer cell death.

Authors:  David Engelmann; Susanne Knoll; Daniel Ewerth; Marc Steder; Anja Stoll; Brigitte M Pützer
Journal:  Cell Mol Life Sci       Date:  2009-12-15       Impact factor: 9.261

3.  Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells.

Authors:  Wan Seok Yang; Brent R Stockwell
Journal:  Chem Biol       Date:  2008-03

4.  The antiapoptotic protein AAC-11 interacts with and regulates Acinus-mediated DNA fragmentation.

Authors:  Patricia Rigou; Valeria Piddubnyak; Audrey Faye; Jean-Christophe Rain; Laurence Michel; Fabien Calvo; Jean-Luc Poyet
Journal:  EMBO J       Date:  2009-04-23       Impact factor: 11.598

5.  Modulation of the E2F1-driven cancer cell fate by the DNA damage response machinery and potential novel E2F1 targets in osteosarcomas.

Authors:  Michalis Liontos; Katerina Niforou; Georgia Velimezi; Konstantinos Vougas; Konstantinos Evangelou; Kalliopi Apostolopoulou; Radek Vrtel; Alexandros Damalas; Panayiotis Kontovazenitis; Athanassios Kotsinas; Vassilis Zoumpourlis; George Th Tsangaris; Christos Kittas; Doron Ginsberg; Thanos D Halazonetis; Jiri Bartek; Vassilis G Gorgoulis
Journal:  Am J Pathol       Date:  2009-06-18       Impact factor: 4.307

6.  miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer.

Authors:  M Karaayvaz; H Zhai; J Ju
Journal:  Cell Death Dis       Date:  2013-06-06       Impact factor: 8.469

7.  Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil.

Authors:  K H Yeh; S H Yeh; C H Hsu; T M Wang; I F Ma; A L Cheng
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

8.  Synthetic lethality: a framework for the development of wiser cancer therapeutics.

Authors:  William G Kaelin
Journal:  Genome Med       Date:  2009-10-27       Impact factor: 11.117

9.  Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage.

Authors:  Peter M Wilson; William Fazzone; Melissa J LaBonte; Heinz-Josef Lenz; Robert D Ladner
Journal:  Nucleic Acids Res       Date:  2008-11-16       Impact factor: 16.971

10.  Prognostic Values of microRNAs in Colorectal Cancer.

Authors:  Yaguang Xi; Andrea Formentini; Minchen Chien; David B Weir; James J Russo; Jingyue Ju; Marko Kornmann; Jingfang Ju
Journal:  Biomark Insights       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.